Effects of Aliskiren on microcirculation dysfunction in patients affected by hypertension

FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点开始时间: 2012年1月10日最近更新: 2012年3月20日

适应症

试验速览

暂无简介。

•Age =40 and =75 yr.
•Body mass index (BMI) =32 kg/m2;
•Diastolic BP (DBP) <110 mmHg and systolic BP (SBP) <180 mmHg in patients previously treated;
•On therapy with amlodipine with or without a thiazide diuretic;
•Left ventricular mass index (LVMI) =115 g/m2 (men) or =100 g/m2 (women) quantified by two dimensional echocardiography;
•Left ventricular ejection fraction =55% at two-dimensional echocardiography;
•Valid informed consent obtained from participants.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 24
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 18

•History of secondary HT;
•Anamnestic coronary heart disease;
•Renal failure (creatinine >1.69 mg/dl or creatinine clearance <30 ml/min);
•Hypokalemia (<3.4 mEq/l) or hyperkalemia (>5 mEq/l);
•Insulin-dependent diabetes;
•Significant valvular disease or left ventricular systolic dysfunction at echocardiography;
•Treatment with Aliskiren, ACE inhibitors or angiotensin receptor blockers in the month preceding the first selection visit;
•Patients with stress-induced regional perfusion defects at PET will be referred for coronary angiography and excluded from the study if they have coronary artery disease;
•Pregnancy and breastfeeding;
•ACEI angioedema, hereditary and/or idiopathic angioedema;
•Severe hepatic dysfunction

发起方

FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR